{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-113158","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.624421+00:00","generated_at":"2026-05-28T23:03:22.150470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights","bullets":["Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.","Cash & equivalents $3.3M; plans to raise additional capital.","R&D expense $11.9M, G&A $18.2M; stock-based compensation $11.8M.","FDA approved LYMPHIR (denileukin diftitox-cxdl) for CTCL; commercial launch expected H1 2025.","Completed Citius Oncology spin-off (CTOR) on Nasdaq in August 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-113158","json":"https://secwatch.observer/filing/0001213900-24-113158.json","markdown":"https://secwatch.observer/filing/0001213900-24-113158.md","text":"https://secwatch.observer/filing/0001213900-24-113158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/0001213900-24-113158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/ea0226161-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:03:22.150470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}